Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12379267 | 1.00 | TDP1 (0.36) | TDP1TSHR | |
| SCHEMBL14668753 | 1.00 | TDP1 (0.36) | TDP1TSHR | |
| SCHEMBL14386229 | 0.91 | TDP1 (0.33) | TDP1 | |
| SCHEMBL17751193 | 0.83 | LMNA (0.43) | TDP1TSHR | |
| SCHEMBL25839232 | 0.83 | LMNA (0.43) | TDP1TSHR | |
| SCHEMBL18653659 | 0.83 | LMNA (0.43) | TDP1TSHR | |
| SCHEMBL8524164 | 0.81 | TDP1 (0.33) | TDP1 | |
| SCHEMBL14363533 | 0.79 | TDP1 (0.32) | TDP1 | |
| SCHEMBL16151822 | 0.79 | LMNA (0.32) | TDP1 | |
| SCHEMBL15947398 | 0.78 | MGAM (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158606-B2 | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | NOVARTIS, AG (CH) | 2012-04-17 | — | — | US | disclosed |
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172178-A1 | BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES | SLC28A2, SLC29A2, PNP | TDP1 760/4885TSHR 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.